Opiant Pharmaceuticals (OPNT) stock price, revenue, and financials

Opiant Pharmaceuticals market cap is $60.9 m, and annual revenue was $13.98 m in FY 2018

$60.9 M

OPNT Mkt cap, 06-Nov-2019

$6.8 M

Opiant Pharmaceuticals Revenue Q2, 2019
Opiant Pharmaceuticals Net income (Q2, 2019)1.6 M
Opiant Pharmaceuticals EBIT (Q2, 2019)1.4 M
Opiant Pharmaceuticals Cash, 30-Jun-201923.9 M

Opiant Pharmaceuticals Income Statement

Annual

USDFY, 2017FY, 2018

Revenue

18.4m14.0m

Revenue growth, %

(24%)

Sales and marketing expense

1.7m213.9k

R&D expense

3.2m8.5m

General and administrative expense

6.5m11.3m

Operating expense total

11.4m35.2m

EBIT

7.1m(21.2m)

EBIT margin, %

38%(152%)

Interest expense

20.0k

Interest income

20.0k144.7k

Pre tax profit

7.1m(21.1m)

Income tax expense

550.5k51.3k

Net Income

6.6m(21.2m)

Quarterly

USDQ2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

13.5m18.1k22.0k1.7m3.2m4.4m5.4m6.8m

Sales and marketing expense

1.2m84.4k

R&D expense

344.8k1.1m1.6m2.4m1.6m1.9m3.6m1.6m

General and administrative expense

1.4m2.0m4.0m3.0m2.9m3.4m3.7m3.7m

Operating expense total

2.9m3.2m5.6m11.0m4.5m5.3m7.3m5.4m

EBIT

10.6m(3.2m)(5.6m)(9.3m)(1.3m)(940.0k)(1.8m)1.4m

EBIT margin, %

79%(17473%)(25482%)(547%)(42%)(22%)(34%)21%

Interest expense

877.010.7k7.0k

Interest income

877.010.7k7.0k5.0k6.0k20.0k122.0k122.0k

Pre tax profit

10.6m(3.1m)(9.3m)(1.4m)(918.0k)(1.7m)1.5m

Income tax expense

33.0k57.0k

Net Income

10.6m(3.1m)(5.6m)(9.3m)(1.4m)(918.0k)(1.7m)1.6m

Opiant Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

254.8k434.2k1.5m6.9m24.6m

Accounts Receivable

312.5k3.8m4.5m

Current Assets

278.8k467.4k1.9m10.8m29.4m

Total Assets

300.7k487.8k1.9m10.8m29.4m

Accounts Payable

200.6k315.5k140.6k2.2m1.1m

Short-term debt

165.0k

Current Liabilities

2.0m3.6m4.2m4.2m9.8m

Total Debt

165.0k

Total Liabilities

3.4m8.9m6.6m6.5m12.5m

Additional Paid-in Capital

43.1m45.0m56.5m58.9m91.3m

Retained Earnings

(46.3m)(53.4m)(61.2m)(54.6m)(74.4m)

Total Equity

(3.1m)(8.4m)(4.7m)4.3m16.9m

Financial Leverage

-0.1 x-0.1 x-0.4 x2.5 x1.7 x

Opiant Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(11.5m)(7.0m)(7.8m)6.6m(21.2m)

Depreciation and Amortization

2.4k5.1k2.6k

Accounts Receivable

(312.5k)7.2m

Accounts Payable

159.8k114.9k(174.9k)2.1m(1.9m)

Cash From Operating Activities

(1.0m)(4.2m)(915.3k)5.6m(523.0k)

Cash From Financing Activities

4.4m(7.5k)(165.0k)17.0m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(1.7m)(6.8m)(7.3m)(775.3k)(11.1m)(7.1m)(6.7m)(600.6k)10.0m6.9m(5.6m)(9.3m)(10.7m)(11.7m)(1.7m)(158.0k)

Depreciation and Amortization

1.3k2.6k1.0k1.0k2.0k2.0k5.0k

Accounts Receivable

(386.6k)312.5k312.5k3.8m10.0m8.7m7.6m2.5m144.0k

Accounts Payable

(16.4k)(27.7k)(21.7k)500.9k615.6k1.3m685.0k221.0k(1.7m)(2.5m)349.0k(59.0k)

Cash From Operating Activities

(274.9k)(431.7k)(671.3k)(974.0k)(748.2k)(356.2k)732.3k(296.8k)11.6m8.4m(970.0k)2.2m678.0k(305.0k)(1.4m)(2.1m)

Purchases of PP&E

(6.5k)(59.0k)

Cash From Investing Activities

(6.5k)(59.0k)

Long-term Borrowings

(165.0k)

Cash From Financing Activities

769.2k1.2m1.2m(165.0k)(165.0k)1.0m2.5m17.0m601.0k1.4m

Opiant Pharmaceuticals Ratios

USDY, 2019

Financial Leverage

1.4 x